Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Oral & Dental

Therapeutic Interventions to Manage Oral Mucositis and Their Impact on Quality of Life in Cancer Patients: An Umbrella Review

This review highlights the most promising interventions for improving QoL in patients with OM. Standardizing QoL measurement and prioritizing patient-reported outcomes in future trials is essential to inform evidence-based supportive oncology care.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

The authors conducted an umbrella review of eight systematic reviews covering 257 primary studies on interventions for oral mucositis and their effect on quality of life in cancer patients. They report consistent quality-of-life improvements with photobiomodulation, honey, black mulberry and SAMITAL, and mixed findings for gabapentin. Heterogeneity in interventions and quality-of-life instruments limited comparability.

Studies included
8
Who or what was studied
Cancer patients with oral mucositis, particularly head and neck cancer patients
Limits stated in the abstract
The authors note heterogeneity in intervention protocols and quality-of-life instruments that limited comparability across reviews.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Background

Oral mucositis (OM) is a debilitating complication of cancer therapy, particularly in head and neck cancer patients, with significant adverse effects on quality of life (QoL). Although numerous interventions have been investigated, their impact on QoL remains inconsistently reported and poorly synthesized.

Methods

An umbrella review was conducted following PRISMA 2020 and Joanna Briggs Institute (JBI) guidelines. Five databases (PubMed, Embase, Scopus, Web of Science, and Cochrane Library) were searched from inception to March 2024. Reviews were eligible if they evaluated any therapeutic intervention for OM and reported QoL-related outcomes using validated tools. Methodological quality was appraised using AMSTAR 2, and findings were narratively synthesized and thematically categorized. The protocol was registered in PROSPERO (CRD420251044088).

Results

Eight systematic reviews (257 primary studies) met the inclusion criteria. Photobiomodulation, honey, black mulberry, and botanical agents such as SAMITAL showed consistent improvement in QoL domains, including pain relief, oral function, and emotional well-being. Gabapentin demonstrated potential in reducing opioid use and early mucositis-related pain, though findings were mixed across trials. QoL was most commonly assessed using the EORTC QLQ-C30, FACT-HN, and UW-QOL. Overall, heterogeneity in intervention protocols and QoL instruments limited comparability.

Conclusions

This review highlights the most promising interventions for improving QoL in patients with OM. Standardizing QoL measurement and prioritizing patient-reported outcomes in future trials is essential to inform evidence-based supportive oncology care.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

How to read a review: what to check before relying on this kind of research.

Terms in this paper: Oral mucositis, Photobiomodulation, Heterogeneity. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies

Oral & Dental

Photobiomodulation for the treatment and prevention of chemotherapy- and/or radiotherapy-induced oral mucositis in cancer patients: a systematic review and meta-analysis of randomized clinical trials published in the last six years

Evidence from recent randomized clinical trials confirms that PBMT is highly effective for the management of oral mucositis, reducing its incidence and severity, improving quality of life and treatment adherence, and potentially lowering healthcare costs during cancer therapy.

Review · May 7, 2026 · G R et al.